Investigating how a protein in the gut affects treatments for obesity and diabetes
Intestinal Reg3g as a mediator of dietary, pharmacological and surgical therapies for obesity and diabetes
This study is looking at how a protein made in the gut affects treatments for obesity and type 2 diabetes, and it aims to help patients understand how their gut health can influence how well these treatments work for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11086091 on NIH RePORTER |
What this research studies
This research explores the role of a specific protein, Reg3g, produced in the gastrointestinal tract and its influence on therapies for obesity and type 2 diabetes. It examines how surgical procedures like vertical sleeve gastrectomy and certain medications can alter gut function and energy balance. By studying the interactions between gut health, bacterial presence, and metabolic regulation, the research aims to uncover new insights that could enhance treatment strategies for these conditions. Patients may benefit from a better understanding of how their gut health impacts their response to various obesity and diabetes therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with obesity or type 2 diabetes, particularly those considering surgical or pharmacological interventions.
Not a fit: Patients without obesity or type 2 diabetes, or those not undergoing any form of treatment for these conditions, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for obesity and type 2 diabetes by leveraging gut health.
How similar studies have performed: Previous research has shown promising results in understanding the gut's role in metabolic regulation, suggesting that this approach could yield significant insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Seeley, Randy J — University of Michigan at Ann Arbor
- Study coordinator: Seeley, Randy J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.